hmvec-ls Search Results


human lung microvascular ecs hmvec-ls  (Cambrex)
90
Cambrex human lung microvascular ecs hmvec-ls
Human Lung Microvascular Ecs Hmvec Ls, supplied by Cambrex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human lung microvascular ecs hmvec-ls/product/Cambrex
Average 90 stars, based on 1 article reviews
human lung microvascular ecs hmvec-ls - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
galectin-treated hmvec-ls  (Galectin Therapeutics)
90
Galectin Therapeutics galectin-treated hmvec-ls
Galectins -2, -4 and -8 induce cytokine secretion from endothelial cells. Human micro-vascular lung endothelial cells were incubated with 1.5 μ g ml −1 galectins -2, -4, -8 or BSA for 24 h before the cytokine levels in the culture media were analysed by the cytokine array ( A ). In ( B ), <t>HMVEC-Ls</t> cells were treated with 1.5 μ g ml −1 galectins -2, -4, -8 or BSA in the presence or absence of 200 μ g ml −1 lactose for 24 h before the G-CSF, IL-6, GRO α and MCP-1 levels in the cultured media were determined by ELISA. The data are expressed as percentage compared with BSA-treated controls from three independent experiments, each in triplicate. * P <0.05, ** P <0.01 (ANOVA, Bonferroni).
Galectin Treated Hmvec Ls, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/galectin-treated hmvec-ls/product/Galectin Therapeutics
Average 90 stars, based on 1 article reviews
galectin-treated hmvec-ls - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
growth factors hmvec-ls  (Lonza)
90
Lonza growth factors hmvec-ls
Galectins -2, -4 and -8 induce cytokine secretion from endothelial cells. Human micro-vascular lung endothelial cells were incubated with 1.5 μ g ml −1 galectins -2, -4, -8 or BSA for 24 h before the cytokine levels in the culture media were analysed by the cytokine array ( A ). In ( B ), <t>HMVEC-Ls</t> cells were treated with 1.5 μ g ml −1 galectins -2, -4, -8 or BSA in the presence or absence of 200 μ g ml −1 lactose for 24 h before the G-CSF, IL-6, GRO α and MCP-1 levels in the cultured media were determined by ELISA. The data are expressed as percentage compared with BSA-treated controls from three independent experiments, each in triplicate. * P <0.05, ** P <0.01 (ANOVA, Bonferroni).
Growth Factors Hmvec Ls, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/growth factors hmvec-ls/product/Lonza
Average 90 stars, based on 1 article reviews
growth factors hmvec-ls - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human pulmonarymicrovascular ecs (hmvecls)  (Cambrex)
90
Cambrex human pulmonarymicrovascular ecs (hmvecls)
Galectins -2, -4 and -8 induce cytokine secretion from endothelial cells. Human micro-vascular lung endothelial cells were incubated with 1.5 μ g ml −1 galectins -2, -4, -8 or BSA for 24 h before the cytokine levels in the culture media were analysed by the cytokine array ( A ). In ( B ), <t>HMVEC-Ls</t> cells were treated with 1.5 μ g ml −1 galectins -2, -4, -8 or BSA in the presence or absence of 200 μ g ml −1 lactose for 24 h before the G-CSF, IL-6, GRO α and MCP-1 levels in the cultured media were determined by ELISA. The data are expressed as percentage compared with BSA-treated controls from three independent experiments, each in triplicate. * P <0.05, ** P <0.01 (ANOVA, Bonferroni).
Human Pulmonarymicrovascular Ecs (Hmvecls), supplied by Cambrex, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human pulmonarymicrovascular ecs (hmvecls)/product/Cambrex
Average 90 stars, based on 1 article reviews
human pulmonarymicrovascular ecs (hmvecls) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Galectins -2, -4 and -8 induce cytokine secretion from endothelial cells. Human micro-vascular lung endothelial cells were incubated with 1.5 μ g ml −1 galectins -2, -4, -8 or BSA for 24 h before the cytokine levels in the culture media were analysed by the cytokine array ( A ). In ( B ), HMVEC-Ls cells were treated with 1.5 μ g ml −1 galectins -2, -4, -8 or BSA in the presence or absence of 200 μ g ml −1 lactose for 24 h before the G-CSF, IL-6, GRO α and MCP-1 levels in the cultured media were determined by ELISA. The data are expressed as percentage compared with BSA-treated controls from three independent experiments, each in triplicate. * P <0.05, ** P <0.01 (ANOVA, Bonferroni).

Journal: British Journal of Cancer

Article Title: Circulating galectins -2, -4 and -8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis

doi: 10.1038/bjc.2013.793

Figure Lengend Snippet: Galectins -2, -4 and -8 induce cytokine secretion from endothelial cells. Human micro-vascular lung endothelial cells were incubated with 1.5 μ g ml −1 galectins -2, -4, -8 or BSA for 24 h before the cytokine levels in the culture media were analysed by the cytokine array ( A ). In ( B ), HMVEC-Ls cells were treated with 1.5 μ g ml −1 galectins -2, -4, -8 or BSA in the presence or absence of 200 μ g ml −1 lactose for 24 h before the G-CSF, IL-6, GRO α and MCP-1 levels in the cultured media were determined by ELISA. The data are expressed as percentage compared with BSA-treated controls from three independent experiments, each in triplicate. * P <0.05, ** P <0.01 (ANOVA, Bonferroni).

Article Snippet: Culture of HUVECs with the conditioned medium obtained from 24 h galectin-treated HMVEC-Ls increased the ability of HUVECs to form microtubule structures (67∼87% increase of branch points and 34∼78% increase of tubule length) in comparison with the HUVECs cultured in the conditioned medium from BSA-treated control HMVEC-Ls ( ).

Techniques: Incubation, Cell Culture, Enzyme-linked Immunosorbent Assay

Galectin-induced cytokine secretion enhances cancer cell-endothelial adhesion. ( A and B ) The presence of galectins -2, -4 or -8 increase cancer cell adhesion to HMVEC-Ls. Human micro-vascular lung endothelial cells were treated with 1.5 μ g ml −1 galectins -2, -4 or -8 for 24 h. The cells were either washed and used for subsequent assessment of ACA19 − ( A ) or HCT116 ( B ) cell adhesion, or the culture medium (CM) were collected and used for subsequent assessment of ACA19 − ( A ) or HCT116 ( B ) cell adhesion. ( C and D ) The galectin-induced cancer cell adhesion is inhibited by lactose. Human micro-vascular lung endothelial cells were treated with 1.5 μ g ml −1 galectins -2, -4 or -8 in the presence or absence of 200 μ g ml −1 lactose for 24 h. The HMVEC-Ls were then used for assessment of ACA19 − ( C ) and HCT116 ( D ) cell adhesion or the culture medium were collected and used for assessment of ACA19 − cell adhesion to fresh HMVEC-Ls ( E ). ( F ) Galectin-mediated cancer cell-endothelial adhesion is inhibited by neutralising anti-cytokine antibodies. Human micro-vascular lung endothelial cells were treated with or without 1.5 μ g ml −1 galectins -2, -4 or -8 in the presence or absence of antibodies against G-CSF (5 ng ml −1 ), IL-6 (3 ng ml −1 ), GRO α (20 ng ml −1 ) and MCP-1(20 ng ml −1 ) in combination for 24 h before ACA19 − adhesion to the HMVEC-Ls was assessed. ( G ) Recombinant cytokines induce cancer cell adhesion to HMVEC-Ls. Human micro-vascular lung endothelial cells were treated without or with a combination of G-CSF (0.25 ng ml −1 ), IL-6 (0.15 ng ml −1 ) and GRO α (1 ng ml −1 ) (combination 1) or G-CSF (0.25 ng ml −1 ), IL-6 (0.15 ng ml −1 ), GRO α (1 ng ml −1 ) and MCP-1 (1 ng ml −1 ) (combination 2) for 24 h before ACA19 − adhesion to HMVEC-Ls was assessed. All the data are expressed as percentage compared with BSA-treated controls from at least three independent experiments, each in triplicate. * P <0.05, ** P <0.01, *** P <0.001 (ANOVA, Bonferroni).

Journal: British Journal of Cancer

Article Title: Circulating galectins -2, -4 and -8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis

doi: 10.1038/bjc.2013.793

Figure Lengend Snippet: Galectin-induced cytokine secretion enhances cancer cell-endothelial adhesion. ( A and B ) The presence of galectins -2, -4 or -8 increase cancer cell adhesion to HMVEC-Ls. Human micro-vascular lung endothelial cells were treated with 1.5 μ g ml −1 galectins -2, -4 or -8 for 24 h. The cells were either washed and used for subsequent assessment of ACA19 − ( A ) or HCT116 ( B ) cell adhesion, or the culture medium (CM) were collected and used for subsequent assessment of ACA19 − ( A ) or HCT116 ( B ) cell adhesion. ( C and D ) The galectin-induced cancer cell adhesion is inhibited by lactose. Human micro-vascular lung endothelial cells were treated with 1.5 μ g ml −1 galectins -2, -4 or -8 in the presence or absence of 200 μ g ml −1 lactose for 24 h. The HMVEC-Ls were then used for assessment of ACA19 − ( C ) and HCT116 ( D ) cell adhesion or the culture medium were collected and used for assessment of ACA19 − cell adhesion to fresh HMVEC-Ls ( E ). ( F ) Galectin-mediated cancer cell-endothelial adhesion is inhibited by neutralising anti-cytokine antibodies. Human micro-vascular lung endothelial cells were treated with or without 1.5 μ g ml −1 galectins -2, -4 or -8 in the presence or absence of antibodies against G-CSF (5 ng ml −1 ), IL-6 (3 ng ml −1 ), GRO α (20 ng ml −1 ) and MCP-1(20 ng ml −1 ) in combination for 24 h before ACA19 − adhesion to the HMVEC-Ls was assessed. ( G ) Recombinant cytokines induce cancer cell adhesion to HMVEC-Ls. Human micro-vascular lung endothelial cells were treated without or with a combination of G-CSF (0.25 ng ml −1 ), IL-6 (0.15 ng ml −1 ) and GRO α (1 ng ml −1 ) (combination 1) or G-CSF (0.25 ng ml −1 ), IL-6 (0.15 ng ml −1 ), GRO α (1 ng ml −1 ) and MCP-1 (1 ng ml −1 ) (combination 2) for 24 h before ACA19 − adhesion to HMVEC-Ls was assessed. All the data are expressed as percentage compared with BSA-treated controls from at least three independent experiments, each in triplicate. * P <0.05, ** P <0.01, *** P <0.001 (ANOVA, Bonferroni).

Article Snippet: Culture of HUVECs with the conditioned medium obtained from 24 h galectin-treated HMVEC-Ls increased the ability of HUVECs to form microtubule structures (67∼87% increase of branch points and 34∼78% increase of tubule length) in comparison with the HUVECs cultured in the conditioned medium from BSA-treated control HMVEC-Ls ( ).

Techniques: Recombinant

Galectin-induced cytokine secretion enhances expression of the endothelial cell surface adhesion molecules, which are responsible for galectin-mediated cancer cell-endothelial adhesion. ( A ) The presence of galectins induces expressions of cell surface adhesion molecules. Human micro-vascular lung endothelial cells were treated with control 1.5 μ g ml −1 BSA (red colour) or 1.5 μ g ml −1 galectins -2 (purple), -4 (brown), -8 (green), a combination of G-CSF (0.25 ng ml −1 ), IL-6 (0.15 ng ml −1 ), GRO α (1 ng ml −1 ), MCP-1 (1 ng ml −1 ) (black) for 24 h before the expressions of the HMVEC surface integrin α v β 1, VCAM-1, CD44 and E-selectin were analysed by flow cytometry. ( B ) The presence of neutralising antibodies against cell surface adhesion molecules inhibits galectins -2, -4 or -8-mediated cancer cell adhesion. Human micro-vascular lung endothelial cells were treated without or with 1.5 μ g ml −1 galectins -2, -4 or -8 for 24 h. The culture media were collected and used to assess ACA19 − cell adhesion to fresh HMVEC-Ls without or with addition of a combination of neutralising antibodies against integrin α v β 1 (10 μ g ml −1 ), CD44 (10 μ g ml −1 ), VCAM-1(10 μ g ml −1 ) and E-selectin (10 μ g ml −1 ). ** P <0.01, *** P <0.001 (ANOVA, Bonferroni).

Journal: British Journal of Cancer

Article Title: Circulating galectins -2, -4 and -8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis

doi: 10.1038/bjc.2013.793

Figure Lengend Snippet: Galectin-induced cytokine secretion enhances expression of the endothelial cell surface adhesion molecules, which are responsible for galectin-mediated cancer cell-endothelial adhesion. ( A ) The presence of galectins induces expressions of cell surface adhesion molecules. Human micro-vascular lung endothelial cells were treated with control 1.5 μ g ml −1 BSA (red colour) or 1.5 μ g ml −1 galectins -2 (purple), -4 (brown), -8 (green), a combination of G-CSF (0.25 ng ml −1 ), IL-6 (0.15 ng ml −1 ), GRO α (1 ng ml −1 ), MCP-1 (1 ng ml −1 ) (black) for 24 h before the expressions of the HMVEC surface integrin α v β 1, VCAM-1, CD44 and E-selectin were analysed by flow cytometry. ( B ) The presence of neutralising antibodies against cell surface adhesion molecules inhibits galectins -2, -4 or -8-mediated cancer cell adhesion. Human micro-vascular lung endothelial cells were treated without or with 1.5 μ g ml −1 galectins -2, -4 or -8 for 24 h. The culture media were collected and used to assess ACA19 − cell adhesion to fresh HMVEC-Ls without or with addition of a combination of neutralising antibodies against integrin α v β 1 (10 μ g ml −1 ), CD44 (10 μ g ml −1 ), VCAM-1(10 μ g ml −1 ) and E-selectin (10 μ g ml −1 ). ** P <0.01, *** P <0.001 (ANOVA, Bonferroni).

Article Snippet: Culture of HUVECs with the conditioned medium obtained from 24 h galectin-treated HMVEC-Ls increased the ability of HUVECs to form microtubule structures (67∼87% increase of branch points and 34∼78% increase of tubule length) in comparison with the HUVECs cultured in the conditioned medium from BSA-treated control HMVEC-Ls ( ).

Techniques: Expressing, Flow Cytometry

Galectins induce cytokine secretion in vivo and the galectin-induced cytokine secretion enhances endothelial tubule formation. Human umbilical vein endothelial cells cultured on matrix proteins were incubated with conditioned medium (CM) obtained from HMVEC-Ls treated with BSA, galectins -2, -4 or -8 (1.5 μ g ml −1 ) for 24 h, with or without introduction to the CM of a combination of neutralising antibodies against G-CSF (5 ng ml −1 ), IL-6(3 ng ml −1 ), GRO α (20 ng ml −1 ) and MCP-1(20 ng ml −1 ) for 24 h at 37 °C. Representative images are shown in ( A ). The tubule length ( B ) and branch points ( C ) were quantified. Data are expressed from three independent experiments, each in triplicate. ( D ) Shows in vivo effect of tail vein injection of 5 μ g galectins -2, -4, -8, individually, or in combination (5 μ g each) on serum levels of the cytokines/chemokines at 0, 24 and 48 h in mice. * P <0.05, ** P <0.01, *** P <0.001 (ANOVA, Bonferroni).

Journal: British Journal of Cancer

Article Title: Circulating galectins -2, -4 and -8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis

doi: 10.1038/bjc.2013.793

Figure Lengend Snippet: Galectins induce cytokine secretion in vivo and the galectin-induced cytokine secretion enhances endothelial tubule formation. Human umbilical vein endothelial cells cultured on matrix proteins were incubated with conditioned medium (CM) obtained from HMVEC-Ls treated with BSA, galectins -2, -4 or -8 (1.5 μ g ml −1 ) for 24 h, with or without introduction to the CM of a combination of neutralising antibodies against G-CSF (5 ng ml −1 ), IL-6(3 ng ml −1 ), GRO α (20 ng ml −1 ) and MCP-1(20 ng ml −1 ) for 24 h at 37 °C. Representative images are shown in ( A ). The tubule length ( B ) and branch points ( C ) were quantified. Data are expressed from three independent experiments, each in triplicate. ( D ) Shows in vivo effect of tail vein injection of 5 μ g galectins -2, -4, -8, individually, or in combination (5 μ g each) on serum levels of the cytokines/chemokines at 0, 24 and 48 h in mice. * P <0.05, ** P <0.01, *** P <0.001 (ANOVA, Bonferroni).

Article Snippet: Culture of HUVECs with the conditioned medium obtained from 24 h galectin-treated HMVEC-Ls increased the ability of HUVECs to form microtubule structures (67∼87% increase of branch points and 34∼78% increase of tubule length) in comparison with the HUVECs cultured in the conditioned medium from BSA-treated control HMVEC-Ls ( ).

Techniques: In Vivo, Cell Culture, Incubation, Injection